Multiple Phase 3 → COMPLETED transitions, led by Lilly's retatrutide TRIUMPH-class trial (n=2335) and AstraZeneca's AZD9550 + AZD6234 dual-combination Phase 2. — 5 trials with material updates.

Competitive Intelligence · Obesity and Type 2 Diabetes

Thursday, June 4, 2026

Multiple Phase 3 → COMPLETED transitions, led by Lilly's retatrutide TRIUMPH-class trial (n=2335) and AstraZeneca's AZD9550 + AZD6234 dual-combination Phase 2.

Key Signals · 5 trials updated

  • Eli Lilly NCT05929066 — retatrutide (GLP-1/GIP/glucagon triple agonist) Phase 3 in obesity/overweight, n=2335, marked COMPLETED (primary completion 2026-04-06). Pivotal readout pending.
  • Eli Lilly NCT06584916 — orforglipron ATTAIN-MAINTAIN Phase 3 weight-maintenance trial (n=376) marked COMPLETED (primary completion 2025-11-21). First oral GLP-1 maintenance readout.
  • AstraZeneca NCT06862791 — AZD9550 + AZD6234 fixed-combination Phase 2 (n=377) marked COMPLETED. First material AZ signal in dual-MOA obesity combo; supports the co-agonist combination thesis from a tracked sponsor.
  • Novo Nordisk NCT05813912 — insulin icodec + semaglutide Phase 3 in T2D (n=148) marked COMPLETED (primary completion 2025-04-14).
  • Novo Nordisk NCT07566390 (NNC0113-5840) and NCT07578584 (NNC0497-0040) — two previously-undisclosed Phase 1 assets recently registered; flagging for Scope-hygiene addition to tracked_molecules.

Material updates (last 24h, LastUpdatePostDate 2026-06-03 / 2026-06-04)

Phase 3 status → COMPLETED

  • NCT05929066 — A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (Eli Lilly, Phase 3, n=2335). PrimaryCompletion 2026-04-06, statusVerified 2026-06. Largest retatrutide obesity Phase 3 — readout will set the benchmark for the GLP-1/GIP/glucagon triple-agonist class. Watch for Lilly press release / ADA-window disclosure.
  • NCT06584916 — Orforglipron ATTAIN-MAINTAIN (Eli Lilly, Phase 3, n=376). PrimaryCompletion 2025-11-21, statusVerified 2026-06. First Phase 3 weight-maintenance trial for an oral small-molecule GLP-1RA — directly addresses the post-discontinuation rebound narrative.
  • NCT05813912 — Insulin Icodec + Semaglutide in T2D (Novo Nordisk, Phase 3, n=148). PrimaryCompletion 2025-04-14, statusVerified 2026-05. Combination weekly-basal + GLP-1 study; supports IcoSema positioning.

Phase 2 status → COMPLETED (tracked sponsor, dual-MOA combination)

  • NCT06862791 — AZD9550 + AZD6234 weight-loss combination Phase 2 (AstraZeneca, n=377). PrimaryCompletion 2026-05-11. This is the first material competitive-intelligence signal from AstraZeneca in our scope this cycle — a co-administration Phase 2 of AZ's GLP-1/glucagon (AZD9550) with AZD6234 (long-acting amylin), placebo-controlled with each monotherapy arm. Read-through to combo regimens (cagrilintide+sema, eloralintide+macupatide). Recommend pulling full results when hasResults flips.

Recruiting Phase 3 with LastUpdatePostDate bump (likely site/contact updates — NOISE)

Lilly's eloralintide Phase 3 cluster (NCT07282600, NCT07321886, NCT07353931, NCT07369011, NCT07392190), retatrutide NCT07357415, orforglipron NCT07153471 / NCT07202884 / NCT06672939, and tirzepatide SURMOUNT-ADOLESCENTS-2 NCT06439277 all had LastUpdatePostDate=2026-06-03/04 with no PCD/SCD/status delta visible at the search-record level. Treating as administrative until a status-history diff suggests otherwise.

Amgen's MariTide trials NCT07226765 (OSA Phase 3) and NCT07441252 (elevated liver fat Phase 2) — recruiting updates, no status transition. Hold.

Pfizer

NCT05546476 (ponsegromab in cancer cachexia) is out of scope (anti-GDF15, oncology cachexia indication) — classifying as noise for this monitor.

Scope hygiene proposals

Novo Nordisk has surfaced two previously-undisclosed Phase 1 obesity assets that should join tracked_molecules:

  • NNC0113-5840 — NCT07566390, Phase 1 in obesity/overweight, n=48, sponsor Novo Nordisk A/S. Newly registered 2026-05-05.
  • NNC0497-0040 — NCT07578584, Phase 1 spanning healthy / overweight / T1D+overweight, n=146. Newly registered 2026-05-11.

These are net-new NNC codes beyond the existing NNC0487-0111 / NNC0662-0419 entries — propose adding to preserve audit trail of why they enter the watchlist.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-06-04T13:47:51.306Z · prompt f8ca428e6d80